- Home
- FULC
as 11-08-2024 4:00pm EST
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Upcoming Earnings Alert:
Get ready for potential market movements as Fulcrum Therapeutics Inc. FULC prepares to release earnings report on 13 Nov 2024.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 221.5M | IPO Year: | 2019 |
| Target Price: | $7.44 | AVG Volume (30 days): | 663.1K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.87 - $13.70 | Next Earning Date: | 11-13-2024 |
| Revenue: | $81,630,000 | Revenue Growth: | 2582.55% |
| Revenue Growth (this year): | 2821.96% | Revenue Growth (next year): | N/A |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
Zacks
14 days ago
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Simply Wall St.
18 days ago
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow
Investor's Business Daily
22 days ago
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
GlobeNewswire
a month ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
a month ago
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
Zacks
a month ago
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
GuruFocus.com
a month ago
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
Compare FULC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.